# Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

> **NCT00366418** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 4 (actual)

## Conditions studied

- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00366418
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-10
- **Primary completion:** 2009-06-11
- **Final completion:** 2009-06-11
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366418, "Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00366418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*